PharmAthene Presents New SparVax® Anthrax Vaccine Data At The American Society For Microbiology 2014 Meeting

ANNAPOLIS, Md., May 29, 2014 /PRNewswire/ — PharmAthene, Inc. (NYSE MKT: PIP) announced today that new analytical data from the Company’s SparVax® anthrax vaccine program were presented at the 114th General Meeting of the American Society for Microbiology (ASM), held recently in Boston, Massachusetts. In a poster presentation entitled “Evidence Correlating Changes in Structure and Biological Activity for a Recombinant Protective Antigen (rPA) Anthrax Vaccine,” Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented the Company’s achievements in developing new analytical methods to measure how changes in the structural characteristics of rPA impact the potency and stability of the vaccine product, an important requirement for licensure by the United States Food and Drug Administration (FDA). Specifically, deamidation of rPA has been identified as the major pathway of degradation, and methods were developed to assess the state of deamidation over time and its relationship to vaccine potency. The results of the study confirmed a strong positive correlation between the structural and functional stability of rPA.